Episeek - Early Cancer Detection Tool
Unlock the life-saving power of Precision Epigemonics early cancer detection tool. EPISEEK identifies over 20 prevalent cancer types, many of which have no other early detection test available.
Detecting the Undectable
When it comes to cancer, early detection is key to saving lives! With 610,000+ cancer deaths in the U.S. each year, most of which stemming from cancer types with no FDA-approved screening options, EPISEEK is making revolutionary strides in detecting cancers that have been previously undetectable in early stages.
The EPISEEK liquid biopsy blood test is intended to be used as a complementary tool to established cancer screening assessments. However in some cases, especially for cancer types that have no previously established screening test and are notoriously hard to detect, it may be the only warning sign currently available for providers.
Unlock the life-saving power of Precision Epigemonics early cancer detection tool. EPISEEK identifies over 20 prevalent cancer types, many of which have no other early detection test available.
Detecting the Undectable
When it comes to cancer, early detection is key to saving lives! With 610,000+ cancer deaths in the U.S. each year, most of which stemming from cancer types with no FDA-approved screening options, EPISEEK is making revolutionary strides in detecting cancers that have been previously undetectable in early stages.
The EPISEEK liquid biopsy blood test is intended to be used as a complementary tool to established cancer screening assessments. However in some cases, especially for cancer types that have no previously established screening test and are notoriously hard to detect, it may be the only warning sign currently available for providers.
Unlock the life-saving power of Precision Epigemonics early cancer detection tool. EPISEEK identifies over 20 prevalent cancer types, many of which have no other early detection test available.
Detecting the Undectable
When it comes to cancer, early detection is key to saving lives! With 610,000+ cancer deaths in the U.S. each year, most of which stemming from cancer types with no FDA-approved screening options, EPISEEK is making revolutionary strides in detecting cancers that have been previously undetectable in early stages.
The EPISEEK liquid biopsy blood test is intended to be used as a complementary tool to established cancer screening assessments. However in some cases, especially for cancer types that have no previously established screening test and are notoriously hard to detect, it may be the only warning sign currently available for providers.